Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
Code effective Jul 01, 2003
HCPCS Section
Commercial Payers (Temporary Codes)
S3840 is a valid 2026 HCPCS code meaning Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2 or (Dna analysis ret-oncogene) for short. HCPCS S3840 has been effective since 07/01/2003 and applies to Other medical items or services.
|
HCPCS Level II Code Section S - Commercial Payers (Temporary Codes) |
|
| HCPCS Code | S3840 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
00 - Physician Fee Schedule And Non-Physician Practitioners - Service not separately priced by part B (e.g., services not covered, bundled, used by Part A only, etc.)
|
| Multiple pricing indicator |
9 - Not applicable as HCPCS not priced separately by part B or value is not established
|
| Coverage code | I - Not payable by Medicare |
| BETOS2 code | Z2 - Undefined codes |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 9 - Other medical items or services |
| Effective date | Effective Jul 01, 2003 |
| Date added | Added Jul 01, 2003 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.